Financials ContraFect Corporation

Equities

CFRXQ

US2123264093

Biotechnology & Medical Research

Market Closed - OTC Markets 03:47:16 2024-05-03 pm EDT 5-day change 1st Jan Change
0.016 USD -8.57% Intraday chart for ContraFect Corporation -11.11% -46.67%

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 74.39 121.5 95.17 140.4 103.4 4.194
Enterprise Value (EV) 1 27.54 91.04 74.88 101.6 52.43 -6.607
P/E ratio -3.62 x -3.09 x -4.02 x -4.08 x -4.77 x -0.06 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -1.05 x -2.94 x -2.7 x -2.98 x -1.11 x 0.12 x
EV / FCF -1.89 x -5.82 x -4.21 x -5.62 x -2.14 x 0.38 x
FCF Yield -53% -17.2% -23.7% -17.8% -46.8% 265%
Price to Book 2.38 x 21.9 x 6.12 x 11.1 x 2.1 x -0.39 x
Nbr of stocks (in thousands) 92.1 99.3 192 348 492 546
Reference price 2 808.0 1,224 496.6 404.0 210.4 7.680
Announcement Date 3/15/18 3/14/19 3/18/20 3/30/21 3/25/22 3/31/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales - - - - - -
EBITDA 1 -26.18 -30.97 -27.7 -34.07 -47.12 -56.74
EBIT 1 -26.36 -31.12 -27.87 -34.24 -47.26 -56.89
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -15.52 -37.68 -12.79 -28.16 -20.28 -65.15
Net income 1 -15.52 -37.68 -12.79 -28.16 -20.28 -65.15
Net margin - - - - - -
EPS 2 -223.3 -396.4 -123.6 -98.95 -44.12 -125.0
Free Cash Flow 1 -14.59 -15.64 -17.78 -18.08 -24.51 -17.53
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/15/18 3/14/19 3/18/20 3/30/21 3/25/22 3/31/23
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3
Net sales 1 - - - - - - - - - -
EBITDA - - - - - - - - - -
EBIT 1 -10.71 -11.69 -14.08 -15.98 -20.03 -14.18 -6.703 -8.858 -7.975 -6.677
Operating Margin - - - - - - - - - -
Earnings before Tax (EBT) 1 -5.396 -5.292 -4.399 -20.16 -18.09 -17.07 -9.839 -1.371 -7.568 -5.359
Net income 1 -5.396 -5.292 -4.399 -20.16 -18.09 -17.07 -9.839 -1.371 -7.568 -5.359
Net margin - - - - - - - - - -
EPS 2 -11.20 -10.40 -8.800 -40.80 -36.80 -34.40 -16.14 -0.6900 -1.940 -0.5000
Dividend per Share - - - - - - - - - -
Announcement Date 8/13/21 11/15/21 3/24/22 5/16/22 8/15/22 11/14/22 3/31/23 5/15/23 8/14/23 11/14/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 46.9 30.5 20.3 38.9 51 10.8
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -14.6 -15.6 -17.8 -18.1 -24.5 -17.5
ROE (net income / shareholders' equity) -61.2% -205% -121% -200% -65.4% -347%
ROA (Net income/ Total Assets) -37.5% -46.8% -51.3% -49.7% -50.1% -81.3%
Assets 1 41.35 80.46 24.93 56.66 40.47 80.11
Book Value Per Share 2 339.0 55.80 81.10 36.30 100.0 -19.90
Cash Flow per Share 2 76.00 83.80 126.0 44.50 33.90 15.00
Capex - 0.13 0.02 - - 0.06
Capex / Sales - - - - - -
Announcement Date 3/15/18 3/14/19 3/18/20 3/30/21 3/25/22 3/31/23
1USD in Million2USD
Estimates
  1. Stock Market
  2. Equities
  3. CFRXQ Stock
  4. Financials ContraFect Corporation